ClinicalTrials.gg
Not yet recruitingNCT07856355TOP-MDRVAPUpdated Oct 2, 2026

Tobramycin Nebulization to Prevent Multidrug-Resistant Ventilator-Associated Pneumonia

A Phase 4 interventional study of Tobramycin inhalation solution and 0.9% Sodium Chloride Placebo in Pneumonia, Ventilator-Associated, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Phase 4, Interventional, and Prevention

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
574
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Pneumonia, Ventilator-Associated with a site in China — 10 open to participants now, 11 under way, none of them phase 3. Pneumonia, Ventilator-Associated · China.

Planned enrollment
2nd of 17
574 · median 174
Started
2026
with 2 others
Phase 4
2 of 26
1 open now
Primary completion
2028-10
later than 9 of 10 live
Registered
26th of 26
by date

Among the 26 studies in Pneumonia, Ventilator-Associated with a site in China, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 4, reaches primary completion later than 9 of the 10 other live ones, and was the 26th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

10 of the 26 studies in Pneumonia, Ventilator-Associated with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Pneumonia, Ventilator-Associated with a site in China, or all of them as a file.
02

Study summary

The TOP-MDRVAP trial will test whether inhaled tobramycin can safely prevent pneumonia caused by multidrug-resistant bacteria in adults who need a breathing machine. Tobramycin is an antibiotic. Multidrug-resistant bacteria are bacteria that resist treatment with several types of antibiotics. Pneumonia that develops in patients receiving breathing support through a breathing tube is called ventilator-associated pneumonia (VAP). This study will evaluate tobramycin as a preventive treatment, rather than as treatment for existing VAP.

The study plans to enroll 574 adults aged 18 years or older in intensive care units (ICUs) at several hospitals. Participants must have received breathing support through a tube for 72 to 96 hours and be expected to need this support for at least another 72 hours. They must have at least one risk factor for infection with multidrug-resistant bacteria and must not have suspected or confirmed VAP when entering the study.

Participants will be assigned by chance to one of two groups, with an equal chance of entering either group. One group will receive tobramycin inhalation solution, 300 mg in 5 mL, twice daily for 3 consecutive days. The other group will receive 5 mL of 0.9% saline, a saltwater solution containing no antibiotic, on the same schedule. A nebulizer will turn the solution into a fine mist delivered through the breathing tube.

Both groups will receive standard measures to prevent VAP. Participants, their representatives, the healthcare professionals providing their direct care, and the researchers assessing outcomes will not know which study treatment each participant receives.

The main question is whether fewer participants develop VAP caused by multidrug-resistant bacteria within 28 days after assignment to a study group. Researchers will also compare the occurrence of VAP from any cause, antibiotic use, time receiving breathing support, time spent in the ICU and hospital, and deaths within 28 and 90 days.

Participants will be monitored for possible side effects, including kidney problems, narrowing of the airways, and complications involving the breathing tube or equipment. Samples will be tested for bacteria and antibiotic resistance. Follow-up will continue for up to 90 days after assignment, using hospital records or telephone contact to assess survival and recovery milestones, including discharge and the end of breathing support.

03

Conditions studied

  • Pneumonia, Ventilator-Associated

Keywords

  • Tobramycin
  • Inhaled Antibiotics
  • Antibiotic Prophylaxis
  • Ventilator-Associated Pneumonia
  • Multidrug-Resistant Bacteria
  • Invasive Mechanical Ventilation
  • Critically Ill Patients
  • Intensive Care Unit
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years at enrollment.
  2. Invasive mechanical ventilation through an endotracheal tube for ≥72 hours and ≤96 hours, measured from the time of intubation, with an anticipated requirement for at least another 72 hours of invasive mechanical ventilation, as assessed by the attending physician.
  3. At least one of the following risk factors for multidrug-resistant (MDR) bacterial infection:

    3.1 Exposure to systemic antibiotics for ≥24 hours within the 30 days before enrollment.

    3.2 Current hospitalization for at least 120 hours before randomization. 3.3 Septic shock requiring vasoactive medication to maintain a mean arterial pressure ≥65 mmHg, with a blood lactate level >2 mmol/L.

    3.4 Moderate-to-severe acute respiratory distress syndrome (ARDS), according to the Berlin definition, with a PaO2/FiO2 ratio ≤200 mmHg and positive end-expiratory pressure (PEEP) ≥5 cm H2O.

    3.5 Current renal replacement therapy, including continuous renal replacement therapy or intermittent hemodialysis.

    3.6 A history of MDR bacterial colonization or infection within the previous 12 months, documented by clinical culture.

  4. Written obtained from the patient or the patient's legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  1. Suspected or confirmed ventilator-associated pneumonia (VAP) on the day of enrollment, based on the attending physician's clinical judgment.
  2. Continuous invasive mechanical ventilation for more than 96 hours before enrollment.
  3. Planned extubation within the next 24 hours.
  4. Previous tracheostomy.
  5. A history of allergy to tobramycin or any other aminoglycoside antibiotic.
  6. Use of tobramycin within the 7 days before enrollment; ongoing treatment with any aminoglycoside antibiotic at enrollment; or a clinical indication for intravenous treatment with any aminoglycoside antibiotic at enrollment.
  7. Chronic kidney disease (stages 4-5) with a baseline estimated (eGFR) ≤30 mL/min/1.73 m², or acute kidney injury meeting the protocol-specified Kidney Disease: Improving Global Outcomes (KDIGO) stage 3 criteria: serum creatinine increased to three times baseline, serum creatinine >353.6 μmol/L, urine output \<0.3 mL/kg/hour for more than 24 hours, or anuria for more than 12 hours. Patients currently receiving renal replacement therapy are exempt from this renal exclusion criterion.
  8. Expected survival of no more than 48 hours, as assessed by the attending physician.
  9. Pregnancy, indicated by a positive serum or urine human chorionic gonadotropin (hCG) test, or breastfeeding.
  10. Concurrent participation in another interventional clinical study involving nebulized antibiotics or other ventilator-associated pneumonia prevention interventions.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
574 participants (estimated)

Study arms

  • Experimental
    Nebulized Tobramycin

    Participants receive tobramycin inhalation solution, 300 mg in 5 mL per dose, administered through the endotracheal tube using a vibrating mesh nebulizer twice daily for 3 consecutive days (6 planned doses). The intervention is administered to prevent multidrug-resistant ventilator-associated pneumonia (MDR-VAP). Participants also receive standard ventilator-associated pneumonia (VAP) prevention measures.

    Drug: Tobramycin inhalation solution

  • Placebo comparator
    Nebulized 0.9% Sodium Chloride Placebo

    Participants receive 5 mL of 0.9% sodium chloride solution (normal saline) as a placebo, administered through the endotracheal tube using a vibrating mesh nebulizer twice daily for 3 consecutive days (6 planned doses). Participants also receive standard ventilator-associated pneumonia (VAP) prevention measures.

    Drug: 0.9% Sodium Chloride Placebo

Interventions

  • DrugTobramycinStudies of TobramycinTobramycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tobramycin inhalation solution (300 mg/5 mL) is administered at a dose of 300 mg (5 mL) twice daily for 3 consecutive days, for a total of 6 planned doses. The ready-to-use solution is administered without additional dilution through the endotracheal tube using a vibrating mesh nebulizer connected to the ventilator circuit. Each nebulization continues until the nebulizer reservoir is empty. The intervention is administered to prevent multidrug-resistant ventilator-associated pneumonia (MDR-VAP), in addition to standard VAP prevention measures.

  • Drug0.9% Sodium Chloride Placebo

    A 5 mL dose of 0.9% sodium chloride solution (normal saline) is administered as a placebo twice daily for 3 consecutive days, for a total of 6 planned doses. The solution is delivered through the endotracheal tube using the same type of vibrating mesh nebulizer, administration schedule, and nebulization procedure as the tobramycin intervention. Each nebulization continues until the nebulizer reservoir is empty. Participants also receive standard VAP prevention measures.

06

What researchers measure

Primary outcomes

  1. 28-Day Cumulative Incidence of Multidrug-Resistant Ventilator-Associated Pneumonia

    Percentage of randomized participants with a first episode of multidrug-resistant ventilator-associated pneumonia (MDR-VAP), adjudicated by an independent blinded endpoint adjudication committee. VAP develops after 48 hours of mechanical ventilation, including within 48 hours after weaning or extubation. Diagnosis requires new or progressive infiltrates, consolidation, or ground-glass opacities on chest X-ray or CT plus at least two of: temperature \>38°C, purulent airway secretions, and white blood cell count \>10 x 10\^9/L or \<4 x 10\^9/L. MDR-VAP additionally requires a positive quantitative lower respiratory tract culture (tracheal aspirate ≥10\^5 CFU/mL; bronchoalveolar lavage ≥10\^4 CFU/mL; protected specimen brush ≥10\^3 CFU/mL) with a causative bacterium resistant to at least three antimicrobial classes.

    Time frame: From randomization through Day 28.

Secondary outcomes

  1. Incidence Density of Multidrug-Resistant Ventilator-Associated Pneumonia

    Number of first episodes of multidrug-resistant ventilator-associated pneumonia per 1,000 invasive mechanical ventilation days accumulated during the assessment period.

    Time frame: From randomization through Day 28.

  2. 28-Day Incidence of Ventilator-Associated Pneumonia From Any Cause

    28-Day Incidence of Ventilator-Associated Pneumonia From Any Cause

    Time frame: From randomization through Day 28.

  3. Systemic Antibiotic Use Expressed as Antibiotic-Days

    Cumulative systemic antibiotic use during the assessment period, expressed as antibiotic-days.

    Time frame: From randomization through Day 28.

  4. Days of Exposure to Systemic Antibiotics

    Number of days on which a participant receives at least one systemic antibiotic during the assessment period. Each day with systemic antibiotic exposure is counted once, regardless of the number of antibiotics administered.

    Time frame: From randomization through Day 28.

  5. Duration of Mechanical Ventilation

    Total duration of invasive and noninvasive mechanical ventilation, measured in days, during the assessment period.

    Time frame: From randomization through Day 28.

  6. Intensive Care Unit Length of Stay

    Duration of intensive care unit stay, measured in days from randomization to ICU discharge, with follow-up through Day 90.

    Time frame: From randomization to ICU discharge, assessed up to Day 90.

  7. Hospital Length of Stay

    Duration of hospital stay, measured in days from randomization to hospital discharge, with follow-up through Day 90.

    Time frame: From randomization to hospital discharge, assessed up to Day 90.

  8. 28-Day All-Cause Mortality

    Percentage of participants who die from any cause within 28 days after randomization.

    Time frame: From randomization through Day 28.

  9. 90-Day All-Cause Mortality

    Percentage of participants who die from any cause within 90 days after randomization. Survival status is obtained from hospital records or telephone follow-up.

    Time frame: From randomization through Day 90.

  10. Incidence of Ventilator-Associated Pneumonia Caused by Tobramycin-Susceptible Gram-Negative Bacteria

    Percentage of participants who develop ventilator-associated pneumonia caused by gram-negative bacteria that are susceptible to tobramycin on in vitro antimicrobial susceptibility testing.

    Time frame: From randomization through Day 28.

  11. Incidence of Ventilator-Associated Events

    Percentage of participants who develop a ventilator-associated event, assessed using the protocol-specified 2023 Centers for Disease Control and Prevention/National Healthcare Safety Network definitions. Assessments include ventilator-associated conditions, infection-related ventilator-associated complications, and possible ventilator-associated pneumonia.

    Time frame: From randomization through Day 28.

  12. Incidence of New-Onset Acute Kidney Injury

    Percentage of participants without acute kidney injury at baseline who develop Kidney Disease: Improving Global Outcomes (KDIGO) stage 1 or higher acute kidney injury during the assessment period.

    Time frame: From randomization through Day 28.

  13. Daily Trajectory of the Clinical Pulmonary Infection Score

    Daily Clinical Pulmonary Infection Score (CPIS) values and their longitudinal changes during the assessment period, calculated using available clinical data.

    Time frame: Assessed daily from randomization until extubation or Day 28, whichever occurs first.

  14. Time to First Successful Spontaneous Breathing Trial

    Time, measured in days, from randomization to the first successful spontaneous breathing trial (SBT) during the assessment period.

    Time frame: From randomization through Day 28.

  15. Detection Rate of Tobramycin-Resistant Bacteria

    Rate of isolation of tobramycin-resistant bacteria from respiratory specimens or blood cultures during the assessment period.

    Time frame: From randomization through Day 28.

  16. Composite Incidence of Serious Nebulization-Related Adverse Effects

    Percentage of participants experiencing at least one serious adverse effect related to nebulization, including increased expiratory filter resistance, bronchospasm, or endotracheal tube obstruction.

    Time frame: From randomization through Day 28.

Other outcomes

  1. Longitudinal Changes in Respiratory Microbiome Alpha Diversity

    Longitudinal changes in respiratory microbiome alpha diversity, assessed by 16S ribosomal RNA amplicon sequencing in participants enrolled in the microbiome substudy.

    Time frame: Protocol-specified Days 1, 4, 7, and 14, with additional sampling at VAP onset.

  2. Longitudinal Changes in Respiratory Microbiome Beta Diversity

    Longitudinal changes in respiratory microbiome beta diversity, assessed by 16S ribosomal RNA amplicon sequencing in participants enrolled in the microbiome substudy.

    Time frame: Protocol-specified Days 1, 4, 7, and 14, with additional sampling at VAP onset.

  3. Longitudinal Changes in Antibiotic Resistance Gene Abundance

    Longitudinal changes in antibiotic resistance gene abundance in respiratory samples, assessed by metagenomic next-generation sequencing.

    Time frame: Protocol-specified Days 1, 4, 7, and 14, with additional sampling at VAP onset.

  4. Longitudinal Changes in Antibiotic Resistance Gene Diversity

    Longitudinal changes in antibiotic resistance gene diversity in respiratory samples, assessed by metagenomic next-generation sequencing.

    Time frame: Protocol-specified Days 1, 4, 7, and 14, with additional sampling at VAP onset.

  5. Tobramycin Concentration-Time Profile in Epithelial Lining Fluid

    Tobramycin concentrations in epithelial lining fluid over time in participants enrolled in the pharmacokinetic substudy.

    Time frame: During the 3-day study treatment period.

  6. Plasma Tobramycin Concentration-Time Profile

    Plasma tobramycin concentrations over time in participants enrolled in the pharmacokinetic substudy.

    Time frame: During the 3-day study treatment period.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the results reported in the primary publication of the TOP-MDRVAP trial will be shared, together with a data dictionary. The dataset will include baseline characteristics, treatment allocation, and data supporting the reported efficacy and safety outcomes. Direct identifiers and the participant identification linkage file will not be shared. Data will be made available through controlled access for approved research proposals, subject to participant consent, institutional and ethics requirements, and applicable data-protection regulations.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data and supporting documents will be available beginning 6 months after publication of the primary trial results and ending 5 years after that publication.

Access criteria: Access will be available to qualified researchers who submit a methodologically sound proposal for secondary analyses or individual participant data meta-analyses. Requests should be submitted to the principal investigator through the study contact listed in the trial registry. The principal investigator and the study Executive Committee will review the scientific merit, feasibility, and data-protection safeguards of each request. Approved applicants must sign a data use agreement limiting use to the approved research, prohibiting participant re-identification and unauthorized onward sharing, and requiring secure data storage. Data will be provided by secure electronic transfer after any required institutional, ethics, or regulatory approvals have been obtained.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 2, 2026
StartEst.
Oct 7, 2026
Primary completionEst.
Oct 31, 2028
CompletionEst.
Jan 29, 2029
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856355
Collaborators
First Affiliated Hospital of Zhejiang University, Sir Run Run Shaw Hospital, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang Hospital, Zhejiang Provincial People's Hospital, Lishui Country People's Hospital, Jinhua People's Hospital, The First People's Hospital of Huzhou, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Qilu Hospital of Shandong University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhengzhou Central Hospital, Second Affiliated Hospital of Nanchang University, West China Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, Weifang People's Hospital, Huang Shan People's Hospital, Jinhua Central Hospital, RenJi Hospital, People's Hospital of Quzhou, Taizhou Hospital, the second people's of kaifeng
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Oct 7, 2026 (estimated)
Primary completion
Oct 31, 2028 (estimated)
Completion
Jan 29, 2029 (estimated)
Last update
Oct 2, 2026

Study contacts

Gensheng Zhang
Contact
genshengzhang@zju.edu.cn
+86 18806812331
Kai Zhang
Contact
zhangkai1993@zju.edu.cn
+86 15150686177

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tobramycin

Start the discussion